| *Sponsored by 60 Degrees Pharmaceuticals, Inc.
Cranking Green On Breaking News, (Nasdaq: SXTP) Reaches The Top Spot On My Watchlist
January 8th
Greetings, Friend!
(Nasdaq: SXTP) is cranking early Wednesday morning.
Making a major green splash, SXTP could be the talk of the town after an important announcement today.
Soak this in:
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
WASHINGTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the first patient has been enrolled in NCT06478641, an expanded access clinical study intended to confirm the activity of tafenoquine in treating patients with persistent babesiosis who have failed standard of care treatment and are at high risk of experiencing a relapse.
“The promise shown by tafenoquine in treating relapsing babesiosis can certainly give patients and physicians reason for hope and optimism,” said Geoff Dow, PhD, chief executive officer of 60 Degrees Pharmaceuticals. “The Tafenoquine for Babesiosis Expanded Access clinical study may strengthen that hope in a patient population that has few treatment options today. We are pleased to be leading the way in supporting that effort.”
...
Read the full article here.
Don't forget. SXTP is a low float idea with roughly 1.5Mn shares in its float.
That means volatility potential could be enormous (especially after today's news).
Consider getting (Nasdaq: SXTP) on your radar quickly this morning. -----
A former Nasdaq champ just caught my attention and could be an early 2025 breakout candidate.
Here's what to focus on at the moment...
- An analyst target suggests over 100%+ upside from Tuesday's open.
- Low float under 2M shares—watch for volatility potential.
- Multiple December press releases reveal head-turning company progress.
Previously, this profile jumped approximately 66% short term, showcasing its explosive potential.
Could round 2 be right around the corner?
Right now I've got my eyes fixed back on: 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP).
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people.
60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018.
And as of this moment, SXTP has 4 key potential catalysts to consider:
#1. A Low Float Could Create An Extremely Volatile Situation (On A Daily Basis).
Yahoo Finance shares SXTP has roughly 1.5Mn shares in its float.
With so few shares available, that means volatility could be extremely explosive at the drop of hate.
#2. An Analyst Target Suggests Potential Upside Of Over 150%!
As of close on Tuesday, January 7th, an Ascendiant Capital Markets analyst target of $3.40 was painting a picture.
That picture? SXTP could be undervalued from current levels.
In fact, there may be a growth potential of over 150% to that target from its closing price Tuesday!
#3. Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
Key Highlights of the Agreement:
- Joint Patent Ownership: 60 Degrees and Tufts MC will co-own patent applications related to tafenoquine for babesiosis, with the Company leading prosecution and maintenance activities worldwide.
- Commercialization Rights: 60 Degrees holds exclusive global rights to commercialize tafenoquine for babesiosis, including sublicensing to third parties for product development and sales.
- Research Collaboration: Tufts MC retains a royalty-free, global license for research purposes, further advancing innovation in this area.
- Royalties and Revenue Sharing: Tufts MC will receive royalties on net sales of tafenoquine-based products labeled for babesiosis treatment or prevention.
- Commitment to Development: 60 Degrees has committed to using commercially reasonable efforts to bring tafenoquine products to market (beyond ARAKODA) and to expanding access to innovative therapies for babesiosis.
#4. 60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
- The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.
- The clinical site is led by Brigham and Women’s Hospital researchers Ann Woolley, M.D., and David Leaf, M.D.
- The double-blind, placebo-controlled trial will examine outcomes for hospitalized patients with severe babesiosis, a tick-borne illness often found as a co-infection of Lyme disease.
Geoffrey Dow, PhD, chief executive officer and president of 60 Degrees Pharmaceuticals shares:
“We are pleased to be collaborating with Brigham and Women’s Hospital on finding answers to the question of how to bring a safe and effective new treatment option to people hospitalized with severe babesiosis, a potentially life-threatening tick-borne illness. [...] In the near term, this collaboration promises to substantially enhance our ability to complete enrollment of this important clinical trial during the 2025 tick season. We look forward to a productive collaboration with the Hospital.” -----
Coverage is officially reinitiated on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP).
I'll be in touch as the week moves forward. Talk again shortly.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, a single member limited liability company. Data is provided from third-party sources and MarketPulseToday is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired by TD Media LLC for a period beginning on 12/9/2024 and ending on 12/10/2024 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”) to disseminate information about (SXTP:US) via digital communications.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired by TD Media LLC for a period beginning on 01/07/2025 and ending on 01/10/2025 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”) to disseminate information about (SXTP:US) via digital communications. These Funds were part of the funds that TD Media LLC received from 60 Degrees Pharmaceuticals Inc., the issuer of (SXTP:US).
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (SXTP:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/sxtp/
The single member of Thousand Sun Media LLC is also the single member of TD Media LLC.
Pursuant to an agreement between TD Media LLC and 60 Degrees Pharmaceuticals Inc., TD Media LLC has been hired for a period beginning on 01/07/2025 and ending on 01/10/2025 to publicly disseminate information about (SXTP:US) via digital communications. To date, including under the previously described agreement, TD Media LLC has been paid one hundred forty-nine thousand USD (“Funds”).These Funds were part of the funds that TD Media LLC received from 60 Degrees Pharmaceuticals Inc., the issuer of (SXTP:US).
Neither TD Media LLC or its member own shares of (SXTP:US).
Please see important disclosure information here: https://lifewatermedia.com/disclosure/sxtp/ | 
No comments:
Post a Comment